Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Vistra Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Vistra Corp trades at $160.51 (market cap $53.42B). The key difference: Vistra Corp is far larger — about 6.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Vistra Corp pays a 0.58% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | VST | |
|---|---|---|
Market Cap | $8.04B | $53.42B |
Sector | Health | Technology |
52-Week High | $339.75 | $217.92 |
52-Week Low | $241.71 | $134.71 |
Enterprise Value | $7.85B | $75.17B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Vistra Corp. (VST) trades at $158.12, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings beating estimates, with revenue growth from $17.74B in 2025 to $19.4B projected for 2026. Net income margin improved to 11.52%, supported by robust cash flow from operations of $4.07B. Recent news highlights Vistra's positioning in the AI power demand surge and long-term power purchase agreements with major tech firms.
Outlook remains positive with a consensus price target of $230.50, implying significant upside. Key opportunities include exposure to growing electricity demand and strategic renewables focus. Risks involve power-price volatility, high debt levels, and execution of growth projects. Analyst sentiment is strongly bullish with 91% buy ratings, though investors should monitor Q2 2026 earnings due August 7 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
